



Alto Neuroscience Announces CEO Amit Etkin, M.D., Ph.D., Named as an Entrepreneur Of The Year® 2023 Bay Area Award Finalist

Entrepreneur Of The Year celebrates ambitious entrepreneurs who are building bolder futures

LOS ALTOS, Calif., May 2, 2023 – Alto Neuroscience today announced that Amit Etkin, M.D., Ph.D., founder and chief executive officer, was named an Entrepreneur Of The Year® 2023 Bay Area Award finalist. Now in its 37th year, Entrepreneur Of The Year by Ernst & Young (EY) is one of the preeminent competitive business awards for transformative entrepreneurs and leaders of high-growth companies who are building a more equitable, sustainable, and prosperous world for all.

Dr. Etkin was selected by an independent panel of judges based on his demonstration of building long-term value through entrepreneurial spirit, purpose, growth, and impact, among other core contributions and attributes.

“I am honored to be recognized as a finalist for EY’s Entrepreneur Of The Year alongside other prominent business leaders in the Bay Area,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. “Departing from my tenured position at Stanford to launch a company felt like quite a leap but has since proven to be well worth the risk. I’m incredibly proud of all we have accomplished to advance new medicines in mental health, and thankful to our dedicated team that has put in the work to make Alto’s vision a reality.”

The Entrepreneur Of The Year program has recognized more than 11,000 entrepreneurs throughout the US since its inception in 1986, and it has grown to recognize business leaders across 145 cities in over 60 countries around the world.

About Entrepreneur Of The Year®

Entrepreneur Of The Year® is the world’s most prestigious business awards program for unstoppable entrepreneurs. These visionary leaders deliver innovation, growth and prosperity that transform our world. The program engages entrepreneurs with insights and experiences that foster growth. It connects them with their peers to strengthen entrepreneurship around the world. Entrepreneur Of The Year is the first and only truly global awards program of its kind. It celebrates entrepreneurs through regional and national awards programs in more than 145 cities in over 60 countries. National Overall Award winners go on to compete for the EY World Entrepreneur Of The Year™ title. Visit ey.com/us/eoy.

About EY

EY exists to build a better working world, helping create long-term value for clients, people and society and build trust in the capital markets. Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate. Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.



EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

About Alto Neuroscience

Alto Neuroscience is pioneering precision psychiatry by developing targeted medicines to help patients get better faster. Differences in individuals' biology impact how they respond to treatment. Alto's Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, behavioral task performance, wearable data, genetics, and other factors to match each patient with the right Alto drug. The company's work in identifying and categorizing core domains of mental function (cognition, emotion, and sleep processes) has resulted in a multiple modality approach that supports robust drug-response predictions. Alto's clinical-stage pipeline includes first- or best-in-class novel drug candidates in depression, PTSD, and other mental health conditions, resulting in the broadest and most-advanced precision psychiatry effort. For more information, visit <https://www.altoneuroscience.com> or [follow us on Twitter](#).

Investor Contact

Nick Smith

corporate@altoneuroscience.com

Media Contact

Jordann Merkert

media@altoneuroscience.com